Biopharmaceutical company developing small-molecule therapeutics for neurodegenerative, neurological, infectious, and other high-unmet-need diseases
Biopharmaceutical company developing small-molecule therapeutics for neurodegenerative, neurological, infectious, and other high-unmet-need diseases. Its proprietary PRISM technology uses computational and physics-based molecular design to create de novo compounds. Lead programs target SARM1 to prevent axonal degeneration and DRP1 to address mitochondrial dysfunction, with preclinical programs for ALS, Parkinson’s disease, Alzheimer’s disease, and related conditions.